As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company. We believe ...

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Shares of contact lens supplier Bausch + Lomb (BLCO) are surging in today ... a company specializing in surgical eye care solutions. How Much Will TPG and BX Be Willing to Pay for BLCO?

We have used Biotrue Hydration Boost Rehydrating ... Over.all, we highly recommend the Sensitive Eyes Contact Lens Solution by Bausch + Lomb for anyone with sensitive eyes who wears soft contact ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.